Specialities

Specialities

Allergic Conditions
Alopecia Areata
Atopic Dermatitis
Autoimmune Endocrine Disorders
Axial Spondyloarthritis
COVID-19
Dermatologic Conditions
Digestive Disorders
Fibromyalgia
Gout
Hematologic Disorders
Hereditary Angioedema
Hidradenitis Suppurativa
Immuno-oncology
Immunology
Inflammatory Bowel Disease
Liver Disorders
Lupus
Musculoskeletal Diseases
Neurological Disorders
Osteoarthritis
Pediatric Dermatology
Pediatric Gastroenterology
Pediatric Rheumatology
Primary Immunodeficiencies
Psoriasis
Psoriatic Arthritis
Rare Autoimmune Diseases
Respiratory Disorders
Rheumatic Diseases
Rheumatoid Arthritis
Sjogren’s Disease
Systemic Sclerosis
Urticaria
Vaccinology
Vasculitis
Vitiligo
Search

Trending Topic

Ankylosing Spondylitis
7 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Diagnosis and management of juvenile axial spondyloarthritis: Lessons and links to adult disease

Dax G Rumsey, Pamela F Weiss

At the American College of Rheumatology (ACR) Convergence 2025, Dr. Pamela Weiss delivered a focused presentation on the diagnosis and management of axial juvenile spondyloarthritis (axJSpA), highlighting key distinctions and overlaps with adult-onset disease. This targeted article synthesizes the principal objectives and takeaways from that session: identification of the characteristic clinical features of axJSpA, the […]

touchREVIEWS in RMD. 2026;6(1):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
Prescribing information (EU) Prescribing information (UK)

Adverse Events Reporting

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting systems.

Adverse events should also be reported to to the Marketing Authorisation holder via Neopharmed Gentili by email: medinfoeurope@neopharmedgentili.com
touchFEATURE

Recognising and optimising management of hereditary angioedema (HAE)

Topics Covered:
Hereditary Angioedema
Feedback
Open Nav

Videos

Hereditary angioedema (HAE): Recognising, referring, and treating to reach normalisation of life

Prof. Andrea Zanichelli, Head of Angioedema Centre, IRCCS Policlinico San Donato, Milan, Italy
Introduction to HAE
Diagnosis & red flags for referral
Burden of HAE
Goals of treatment and a Treat-to-Target approach
Reaching normalisation of life with long-term prophylaxis (LTP)
Switching LTP for optimal outcomes
Duration: 23:13

Identifying red flags for referral and optimising treatment to reach normalisation of life: Patient case study in HAE

Dr Mar Guilarte, Head of the Angioedema Unit in the Department of Allergy, VHIR (Vall d’Hebron Research Institute), Barcelona, Spain
From symptoms to diagnosis: Maria’s journey
Treatment optimisation through a Treat-to-Target approach
Switching from androgens
Reaching normalisation of life with oral LTP
Duration: 14:40

Got 2 minutes?

Your feedback is important to us.

1
Strongly Disagree
5
Strongly Agree
*
Mandatory Field

Your responses are anonymous and will be reviewed by Neopharmed Gentili to improve future educational programmes and materials.

Back to Activity
Submit Feedback Submit Feedback
Complete Above Form

Please complete the below so we can prepare your certificate download.

touchFEATURE

Recognising and optimising management of hereditary angioedema (HAE)

Back
Submit Accreditation Submit Accreditation
Complete Above Form
touchIMMUNOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchIMMUNOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Videos

Hereditary angioedema (HAE): Recognising, referring, and treating to reach normalisation of life

Prof. Andrea Zanichelli, Head of Angioedema Centre, IRCCS Policlinico San Donato, Milan, Italy
Introduction to HAE
Diagnosis & red flags for referral
Burden of HAE
Goals of treatment and a Treat-to-Target approach
Reaching normalisation of life with long-term prophylaxis (LTP)
Switching LTP for optimal outcomes
Duration: 23:13

Identifying red flags for referral and optimising treatment to reach normalisation of life: Patient case study in HAE

Dr Mar Guilarte, Head of the Angioedema Unit in the Department of Allergy, VHIR (Vall d’Hebron Research Institute), Barcelona, Spain
From symptoms to diagnosis: Maria’s journey
Treatment optimisation through a Treat-to-Target approach
Switching from androgens
Reaching normalisation of life with oral LTP
Duration: 14:40

Activity Overview

Contact Neopharmed Gentili

Activity Overview
Contact Neopharmed Gentili
Feedback

Overview

Hereditary angioedema (HAE) is a rare, potentially life-threatening condition that can have a profound impact on patients’ daily lives. Early recognition and accurate diagnosis are essential to improving outcomes, yet diagnostic delays remain common.1

Discover how timely recognition of HAE symptoms and a Treat-to-Target approach can support improved outcomes in HAE. In this two-part expert series:

  • Prof. Andrea Zanichelli outlines key red flags, explains the Treat-to-Target approach, and explores how oral LTP can help patients achieve their short- and long-term targets
  • Dr Mar Guilarte shares a real-world case showing how Treat-to-Target principles can be applied in everyday clinical practice and support patients reach normalisation of life

Learning Objectives

After watching this activity, participants should be better able to:

  • Understand what HAE is and the multifaceted burden of disease
  • Identify clinical red flag symptoms and understand how to validate HAE attacks to support earlier and more accurate diagnosis
  • Understand the current treatment landscape for HAE, and recognise that long-term prophylaxis (LTP) is the only treatment approach that can currently achieve optimal treatment goals – complete disease control and normalisation of life2

References2

List View
Grid View
1

Banerji A. Ann Allergy Asthma Immunol. 2013;111:329–36

2

Maurer M, et al. Allergy. 2022;77:1961–90.

Contact Neopharmed Gentili

If you would like to contact Neopharmed Gentili for more information, please click here.

By clicking the link you will be leaving touchIMMUNOLOGY.

Video Navigation

Videos

Hereditary angioedema (HAE): Recognising, referring, and treating to reach normalisation of life

Prof. Andrea Zanichelli, Head of Angioedema Centre, IRCCS Policlinico San Donato, Milan, Italy
Introduction to HAE
Diagnosis & red flags for referral
Burden of HAE
Goals of treatment and a Treat-to-Target approach
Reaching normalisation of life with long-term prophylaxis (LTP)
Switching LTP for optimal outcomes
Duration: 23:13

Identifying red flags for referral and optimising treatment to reach normalisation of life: Patient case study in HAE

Dr Mar Guilarte, Head of the Angioedema Unit in the Department of Allergy, VHIR (Vall d’Hebron Research Institute), Barcelona, Spain
From symptoms to diagnosis: Maria’s journey
Treatment optimisation through a Treat-to-Target approach
Switching from androgens
Reaching normalisation of life with oral LTP
Duration: 14:40

Add a Note

Note Time: 00:00
Save Note
touchIMMUNOLOGY
touchFEATURE

This content is intended for healthcare professionals in specific countries only.

Please confirm that you are a healthcare professional in one of these countries: Denmark, Finland, France, Germany, Iceland, Ireland, Italy, Norway, Spain, Sweden, UK

Register
Login

To access this content.

This promotional microsite is funded by BioCryst Ireland Ltd, a Neopharmed Gentili company, which provided financial support, content and editorial control in the production. This activity is provided by Touch Medical Communications (TMC) for touchIMMUNOLOGY.

Date of preparation: March 2026 | EU.ORL.00254

Close Popup
touchIMMUNOLOGY
touchFEATURE

This content is intended for healthcare professionals in specific countries only.

Please confirm that you are a healthcare professional in one of these countries: Denmark, Finland, France, Germany, Iceland, Ireland, Italy, Norway, Spain, Sweden, UK

Continue
Decline

This promotional microsite is funded by BioCryst Ireland Ltd, a Neopharmed Gentili company, which provided financial support, content and editorial control in the production. This activity is provided by Touch Medical Communications (TMC) for touchIMMUNOLOGY.

Date of preparation: March 2026 | EU.ORL.00254

Close Popup
touchIMMUNOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage

This promotional microsite is funded by BioCryst Ireland Ltd, a Neopharmed Gentili company, which provided financial support, content and editorial control in the production.

This activity is provided by Touch Medical Communications (TMC) for touchIMMUNOLOGY.

This promotional microsite is intended for healthcare professionals only.

TMC accepts no responsibility for errors or omissions.

Date of preparation: March 2026 | EU.ORL.00254

 

Latest articles videos and clinical updates - straight to your inbox

Close Popup